NCT07102095: A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose

Sponsor: Bayer. Phase: PHASE1. Conditions: Hepatic Insufficiency, Liver Diseases, Pharmacokinetics, Drug Metabolism